DPP-4 inhibitorincretin enhancerincretin mimeticstype 2 diabetes mellitusmode of actionOver the last few years, the incretin-based therapies have emerged as important agents in the treatment of type 2 diabetes (T2D). These agents exert their effect via the incretin system, specifically targeting the...
DPP-4 inhibitorincretin enhancerincretin mimeticstype 2 diabetes mellitusmode of actionOver the last few years, the incretin-based therapies have emerged as ... M Nauck - 《Diabetes Obesity & Metabolism》 被引量: 126发表: 2015年 Linagliptin: A New DPP-4 Inhibitor for the Treatment of Type 2...
Dipeptidyl peptidase-4 (DPP-4) inhibitors are glucose-lowering drugs for type 2 diabetes mellitus (T2DM). We investigated whether evogliptin® (EVO), a DPP-4 inhibitor, could protect against diabetic cardiomyopathy (DCM) and the underlying mechanisms. Eight-week-old diabetic and obese db/db...
However, active GLP-1 in the circulation is rapidly (within two minutes) degraded by dipeptidyl peptidase-4 (DPP-4) [15]. An alternative approach for enhancing GLP-1 action involves the use of DPP-4 inhibitors. The DPP-4 inhibitor sitagliptin [16] and saxagliptin [17] have been approved ...
www.nature.com/scientificreports OPEN DPP-4 Inhibitor and Estrogen Share Similar Efficacy Against Cardiac Ischemic-Reperfusion Injury received: 26 September 2016 in Obese-Insulin Resistant andaccepted:07February2017 Published:10March2017 Estrogen-Deprived Female Rats Sivaporn Sivasinprasasn1,2,3,4, ...
1.2.2.2 分子对接筛选 应用 Discovery Studio2019 软件中的 Dock Ligands(CDOCKER)工具对肽段与 DPP-IV(PDB ID:4A5S)进行半柔性分子对接,按照 分子对接步骤设定相关参数 , 以 -CDOCKER_EN- ERGY 和 -CDOCKER_INTERACTION_ENERGY 为评分指标,筛选目标活性肽."-CDOCKER_IN- TERACTION_ENERGY"值是受体与配体相互...
A new DPP-4 inhibitor class of oral anti-diabetic medicines, working by the novel mechanism of incretin enhancement, is poised to revolutionise the management of Type 2 diabetes. Data presented at a recent European Association for the Study of Diabetes meeting suggest the...
As a reminder, the trial is exploring the efficacy of DA-1241 independently, as well as in combination with sitagliptin, a DPP-4 inhibitor, which we believe will show synergistic effects compared to DA-1241, alone. Based on pre-clinical and clinical evidence generated to date, we continue ...
Where, “Fc” and “Ss” were fluorescence of the control (without inhibitor) and test samples (extract or inhibitor) respectively. 2.5. Cell culture assays 2.5.1. Glucose utilization study in 3T3-L1 adipocytes and Chang liver cells Assays were performed according to previously reported methods ...
In addition, MLPLML can also bind to Val656 and Trp659, which are the same amino acids bound by the commercial inhibitor saxagliptin. We further found that PAVACCL (H12), PPLPCHM, and YDFL (H5), and PAGNFLP and PVAAAPVM (H12), could bind to 5 and 4 important active site residues...